NCT00085488

Brief Summary

RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Feb 2004

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2004

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 10, 2004

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 11, 2004

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2006

Completed
Last Updated

February 2, 2015

Status Verified

October 1, 2005

Enrollment Period

2 years

First QC Date

June 10, 2004

Last Update Submit

January 30, 2015

Conditions

Melanoma (Skin)

Keywords

recurrent melanomastage III melanomastage IV melanoma

Outcome Measures

Primary Outcomes (1)

  • Ex Vivo Matured Dendritic Cell Therapy in Patients with Melanoma

    2005-2006

Interventions

autologous tumor cell vaccineBIOLOGICAL
therapeutic autologous dendritic cellsBIOLOGICAL

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: * Histologically confirmed melanoma * Stage III (lymph node or in-transit metastases) or IV (systemic metastases) disease * Patients with relapsed disease OR who failed prior immunotherapy or chemotherapy are eligible (but trial not restricted to relapsed or refractory disease) * Tumor tissue available and properly stored for lysate preparation PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 60-100% Life expectancy * At least 12 weeks Hematopoietic * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 75,000/mm\^3 Hepatic * AST ≤ 2 times upper limit of normal (ULN) (3 times ULN for liver metastases) * Bilirubin ≤ 2 times ULN * Hepatitis B surface antigen negative * Hepatitis C negative Renal * Creatinine ≤ 2.0 times ULN Immunologic * No active infection * No history of autoimmune disease, including any of the following: * Inflammatory bowel disease * Systemic lupus erythematosus * Scleroderma * Rheumatoid arthritis * Multiple sclerosis * No allergy to aminoglycosides or streptomycin * HIV negative Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No significant comorbid illness * No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * At least 10 days since prior immunotherapy Chemotherapy * See Disease Characteristics Endocrine therapy * At least 6 weeks since prior steroid therapy * No concurrent corticosteroids Radiotherapy * At least 10 days since prior radiotherapy * No concurrent radiotherapy Surgery * At least 10 days since prior surgery * Prior diagnostic or palliative surgery allowed provided the patient has fully recovered Other * No concurrent immunosuppressive or potentially immunosuppressive therapy

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756-0002, United States

Location

MeSH Terms

Conditions

Melanoma

Interventions

FANG vaccine

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Christopher P. Tretter, MD

    Norris Cotton Cancer Center

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 1
Purpose
TREATMENT
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2004

First Posted

June 11, 2004

Study Start

February 1, 2004

Primary Completion

February 1, 2006

Study Completion

February 1, 2006

Last Updated

February 2, 2015

Record last verified: 2005-10

Locations

US(1)